05 Nov A major step for the polyvalent HIV vaccine – WHV manufactures world’s first four-valent gp120 protein vaccine
Posted at 17:11h in Featured, URP News, UW Madison News
Working with Waisman Biomanufacturing, WHV scientists manufactured a novel 4-valent gp120 protein vaccine for further clinical testing of its preventive HIV vaccine candidate PDPHV.
Previously, the laboratory of Dr. Shan Lu at the University of Massachusetts Medical School (UMMS) developed the polyvalent HIV vaccine including both DNA and protein components. In recently conducted phase I clinical trial HVTN124 supported by US NIH/NIAID, four gp120 proteins from the four major clades of HIV-1 (A, B, C, and AE) were individually vialed. The proteins had to be mixed with each other and with the GLA-SE adjuvant at bedside prior to administration.